Diligence memo · auto-generated · as of July 2, 2026
Boundless Bio, Inc.
Boundless Bio, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Boundless Bio, Inc. operates in Biotechnology, based in San Diego.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Boundless Bio, Inc. has raised $229M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $106M on 2021-04-23.
Most recent recorded round closed around 2023-04-05.
Valuation (modeled)modeled
Provath models Boundless Bio, Inc. at approximately $1.7B (range $453M–$2.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.82× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era. Within the normal band (82% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 28 months.
Last raise 3.2 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 97% of Biotechnology peers (4293 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.